3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
10
Melanoma
9
Neoplasm Metastasis
4
Clear-cell metastatic renal cell carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Prostatic Neoplasms
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Carcinoma, Transitional Cell
3
Carcinoma, Basal Cell
3
Urogenital Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Thyroid Neoplasms
2
Sarcoma
2
Penile Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Lung Neoplasms
2
Histiocytoma, Malignant Fibrous
2
Glioblastoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Endometrioid
2
Brain Neoplasms
2
Adenocarcinoma of Lung
2
Vulvar Neoplasms
1
Uveal Melanoma
1
Ureteral Neoplasms
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
talazoparib
1
olaparib
1
irinotecan sucrosofate
1
amino-acid, glucose, and electrolyte solution
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
CTLA-4 Antigen
×
90 days
×
Clear all
No trials found.